Related Experiment Video
Updated: Jun 19, 2026
09:47
Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes
Published on: February 19, 2016
9.7K
Layered double hydroxide nanocarriers: potential delivery systems for mefenamic acid
Parteek Prasher1, Mousmee Sharma2
1Department of Chemistry, University of Petroleum & Energy Studies, Energy Acres, Dehradun, 248007, India.
Nanomedicine (London, England)
|October 25, 2023
Summary
Layered double hydroxide nanocarriers effectively load hydrophobic nonsteroidal anti-inflammatory drugs (NSAIDs), like mefenamic acid. This intercalation enhances drug delivery, improving NSAID pharmacokinetics and bioavailability.
Area of Science:
- Materials Science
- Nanotechnology
- Pharmacology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) often suffer from poor solubility and bioavailability.
- Layered double hydroxides (LDHs) are versatile nanomaterials with potential for drug delivery applications.
Purpose of the Study:
- To investigate the intercalation of hydrophobic NSAIDs into LDH nanocarriers.
- To evaluate the impact of LDH intercalation on NSAID pharmacokinetics and bioavailability.
Main Methods:
- Synthesis and characterization of LDH nanocarriers.
- Intercalation of mefenamic acid into LDH structures.
- In vitro and in vivo pharmacokinetic studies.
Main Results:
- Successful intercalation of mefenamic acid within the LDH structure was confirmed.
- LDH-intercalated mefenamic acid demonstrated significantly improved pharmacokinetic profiles.
- Enhanced bioavailability of mefenamic acid was observed following LDH delivery.
Conclusions:
- LDH nanocarriers represent a promising platform for improving the delivery of hydrophobic NSAIDs.
- Intercalation into LDHs can overcome bioavailability limitations of certain NSAIDs, enhancing their therapeutic potential.
More Related Videos
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...